Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.77 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | DRD3 | P35462 | 1/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.77 |
| ▸ | GABRA1 | P14867 | 8/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 8/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 8/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 6/20 | 0.51 |
| ▸ | PTAFR | P25105 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | MC3R | P41968 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7307929 | 0.87 | CYP3A4 (0.77) | CYP3A4OPRK1SLC22A1ABCB11DRD3 | |
| Midazolam SCHEMBL29565146 | 0.87 | OPRK1 (1.00) | CYP3A4OPRK1SLC22A1ABCB11DRD3 | |
| Midazolam SCHEMBL5783371 | 0.87 | OPRK1 (1.00) | CYP3A4OPRK1SLC22A1ABCB11DRD3 | |
| SCHEMBL7309516 | 0.87 | CYP3A4 (0.77) | CYP3A4OPRK1SLC22A1ABCB11DRD3 | |
| SCHEMBL13320809 | 0.87 | GABRA1 (0.68) | CYP3A4OPRK1SLC22A1ABCB11DRD3 | |
| Midazolam SCHEMBL29735381 | 0.87 | OPRK1 (1.00) | CYP3A4OPRK1SLC22A1ABCB11DRD3 | |
| Midazolam SCHEMBL29480459 | 0.87 | OPRK1 (1.00) | CYP3A4OPRK1SLC22A1ABCB11DRD3 | |
| Midazolam SCHEMBL35061 | 0.87 | OPRK1 (1.00) | CYP3A4OPRK1SLC22A1ABCB11DRD3 | |
| Midazolam SCHEMBL29357425 | 0.87 | OPRK1 (1.00) | CYP3A4OPRK1SLC22A1ABCB11DRD3 | |
| Midazolam SCHEMBL41265 | 0.86 | OPRK1 (0.98) | CYP3A4OPRK1SLC22A1ABCB11DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130481-A1 | ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| US-20100130481-A1 | ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130481-A1 | ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS | GABRA3, GABRA2, GABRA1 | CYP3A4 392/4885OPRK1 72/4885SLC22A1 1841/4885 |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | CYP3A4 290/4885OPRK1 173/4885SLC22A1 1859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.